Hormone Immunoassay Interference: A 2021 Update

키워드

참고문헌 (196)

1. Wu AH, "A selected history and future of immunoassay development and applications in clinical chemistry", Clin Chim Acta, 369, pp.119~124 (2006)
2. Sturgeon CM, "Analytical error and interference in immunoassay : minimizing risk", Ann Clin Biochem, 48, pp.418~432 (2011)
3. Köhler G, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, 256, pp.495~497 (1975)
4. Tate J, "Interferences in immunoassay", Clin Biochem Rev, 25, pp.105~120 (2004)
5. Sturgeon CM, "External quality assessment of hormone determinations", Best Pract Res Clin Endocrinol Metab, 27, pp.803~822 (2013)
6. Darwish IA, "Immunoassay methods and their applications in pharmaceutical analysis : basic methodology and recent advances", Int J Biomed Sci, 2, pp.217~235 (2006)
7. Caruso B, "Causes of preanalytical interferences on laboratory immunoassays–A critical review", EJIFCC, 31, pp.70~84 (2020)
8. Gnocchi D, "Circadian rhythms and hormonal homeostasis: pathophysiological implications", Biology(Basel), 6, pp.10~ (2017)
9. Long N, "PURLS : It’s time to reconsider early-morning testosterone tests", J Fam Pract, 64, pp.418~419 (2015)
10. Selby C, "Interference in immunoassay", Ann Clin Biochem, 36, pp.704~721 (1999)
11. Owen LJ, "Oestradiol measurement during fulvestrant treatment for breast cancer", Br J Cancer, 120, pp.404~406 (2019)
12. Mandic S, "Falsely elevated serum oestradiol due to exemestane therapy", Ann Clin Biochem, 54, pp.402~405 (2017)
13. Valdes R, "Unexpected suppression of immunoassay results by cross-reactivity : now a demonstrated cause for concern", Clin Chem, 48, pp.405~406 (2002)
14. Lopez AG, "Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma", Ann Endocrinol(Paris), 80, pp.250~258 (2019)
15. Groenestege WM, "Accuracy of first and second generation testosterone assays and improvement through sample extraction", Clin Chem, 58, pp.1154~1156 (2012)
16. Benton SC, "Measured dehydroepiandrosterone sulfate positively influences testosterone measurement in unextracted female serum : comparison of 2 immunoassays with testosterone measured by LC-MS", Clin Chem, 57, pp.1074~1075 (2011)
17. Honour JW, "Steroid assays in paediatric endocrinology", J Clin Res Pediatr Endocrinol, 2, pp.1~16 (2010)
18. Paisley AN, "Pegvisomant interference in GH assays results in underestimation of GH levels", Eur J Endocrinol, 156, pp.315~319 (2007)
19. Manolopoulou J, "Automated 22-kD growth hormone-specific assay without interference from Pegvisomant", Clin Chem, 58, pp.1446~1456 (2012)
20. RaffH, "A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing’s syndrome", Clin Chem, 35, pp.596~600 (1989)
21. Woeber KA, "Recurrent pituitary macroadenoma with increased plasma ACTH precursors that cross-react in a commonly used ACTH immunoassay", Endocr Pract, 20, pp.94~96 (2014)
22. Parfitt C, "Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues", Clin Biochem, 48, pp.1354~1357 (2015)
23. Dayaldasani A, "Cross-reactivity of insulin analogues with three insulin assays", Ann Clin Biochem, 52, pp.312~318 (2015)
24. Giurgea I, "Factitious hyperinsulinism leading to pancreatectomy : severe forms of Munchausen syndrome by proxy", Pediatrics, 116, pp.e145~e148 (2005)
25. Drees JC, "Falsely undetectable TSH in a cohort of South Asian euthyroid patients", J Clin Endocrinol Metab, 99, pp.1171~1179 (2014)
26. Ward G, "The investigation of interferences in immunoassay", Clin Biochem, 50, pp.1306~1311 (2017)
27. Haddad RA, "Interpretation of common endocrine laboratory tests: technical pitfalls, their mechanisms and practical considerations", Clin Diabetes Endocrinol, 5, pp.12~ (2019)
28. Frieze TW, ""Hook effect"in prolactinomas : case report and review of literature", Endocr Pract, 8, pp.296~303 (2002)
29. Bolstad N, "Heterophilic antibody interference in immunometric assays", Best Pract Res Clin Endocrinol Metab, 27, pp.647~661 (2013)
30. Ismail AA, "Identifying and reducing potentially wrong immunoassay results even when plausible and"not-unreasonable"", Adv Clin Chem, 66, pp.241~294 (2014)
31. Favresse J, "Interferences with thyroid function immunoassays : clinical implications and detection algorithm", Endocr Rev, 39, pp.830~850 (2018)
32. Kricka LJ, "Human anti-animal antibody interferences in immunological assays", Clin Chem, 45, pp.942~956 (1999)
33. Bergman D, "Characterization of canine anti-mouse antibodies highlights that multiple strategies are needed to combat immunoassay interference", Sci Rep, 9, pp.14521~ (2019)
34. Boscato LM, "Heterophilic antibodies : a problem for all immunoassays", Clin Chem, 34, pp.27~33 (1988)
35. Hattori N, "Variability in the detection of macro TSH in different immunoassay systems", Eur J Endocrinol, 174, pp.9~15 (2016)
36. Giovanella L, "Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma", Clin Chem, 53, pp.1871~1872 (2007)
37. Ramaeker D, "When is elevated testosterone not testosterone? When it is an immunoassay interfering antibody", Fertil Steril, 90, pp.886~888 (2008)
38. Brugts MP, "Heterophilic antibodies may be a cause of falsely low total IGF1 levels", Eur J Endocrinol, 161, pp.561~565 (2009)
39. Saleem M, "A patient with pseudo-Addison’s disease and falsely elevated thyroxine due to interference in serum cortisol and free thyroxine immunoassays by two different mechanisms", Ann Clin Biochem, 46, pp.172~175 (2009)
40. Gulbahar O, "A case with immunoassay interferences in the measurement of multiple hormones", J Clin Endocrinol Metab, 100, pp.2147~2153 (2015)
41. García-González E, "Serum sample containing endogenous antibodies interfering with multiple hormone immunoassays. Laboratory strategies to detect interference", Pract Lab Med, 4, pp.1~10 (2015)
42. Oei AL, "Transient human anti-mouse antibodies(HAMA)interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody", Gynecol Oncol, 109, pp.199~202 (2008)
43. Kazmierczak SC, "Transient nature of interference effects from heterophile antibodies : examples of interference with cardiac marker measurements", Clin Chem Lab Med, 38, pp.33~39 (2000)
44. Berglund Land Holmberg NG, "Heterophilic antibodies against rabbit serum causing falsely elevated gonadotropin levels", Acta Obstet Gynecol Scand, 68, pp.377~378 (1989)
45. Klee GG, "Interferences in hormone immunoassays", Clin Lab Med, 24, pp.1~18 (2004)
46. Ismail AA, "On the diagnosis of subclinical hypothyroidism", Br J Gen Pract, 57, pp.1000~1001 (2007)
47. Lu RM, "Development of therapeutic antibodies for the treatment of diseases", J Biomed Sci, 27, pp.1~ (2020)
48. Castinetti F, "French endocrine society guidance on endocrine side effects of immunotherapy", Endocr Relat Cancer, 26, pp.G1~G18 (2019)
49. Lahlou N, "Expert opinions on endocrine toxicity induced by new anticancer therapies: precautions to be taken in performing and interpreting hormonal assays under immunotherapy", Ann Endocrinol(Paris), 79, pp.550~554 (2018)
50. Koshida S, "Prevalence of human anti-mouse antibodies(HAMAs)in routine examinations", Clin Chim Acta, 411, pp.391~394 (2010)
51. Emerson JF, "Endogenous antibody interferences in immunoassays", Lab Med, 44, pp.69~73 (2013)
52. Jonklaas J, "TSH-free thyroxine discordance in an athyreotic patient during ipiluminab and nivoluminab therapy", AACE Clin Case Rep, 2, pp.e296~e301 (2016)
53. Kim D, "Heterophile antibody interference associated with natural killer cell therapy", Endocr J, 67, pp.1187~1192 (2020)
54. Holm BE, "Species cross-reactivity of rheumatoid factors and implications for immunoassays", Scand J Clin Lab Invest, 75, pp.51~63 (2015)
55. Astarita G, "False positive in the measurement of thyroglobulin induced by rheumatoid factor", Clin Chim Acta, 447, pp.43~46 (2015)
56. Mongolu S, "Heterophilic antibody interference affecting multiple hormone assays : is it due to rheumatoid factor?", Scand J Clin Lab Invest, 76, pp.240~242 (2016)
57. Cheng X, "Heterophilic antibody interference with TSH measurement on different immunoassay platforms", Clin Chim Acta, 512, pp.63~65 (2021)
58. Laudes M, "PTH immunoassay interference due to human anti-mouse antibodies in a subject with obesity with normal parathyroid function", J Clin Endocrinol Metab, 104, pp.5840~5842 (2019)
59. Fruzzetti F, "Anti-goat antibodies as a rare cause of high gonadotropin levels during menopausal transition", Gynecol Endocrinol, 36, pp.938~940 (2020)
60. Aliberti L, "Hypeprolactinemia : still an insidious diagnosis", Endocrine, 72, pp.928~931 (2021)
61. Hattori N, "A possible cause of the variable detectability of macroprolactin by different immunoassay systems", Clin Chem Lab Med, 54, pp.603~608 (2016)
62. Overgaard M, "Serum prolactin revisited : parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia", Clin Chem Lab Med, 55, pp.1744~1753 (2017)
63. Fahie-Wilson M, "Determination of prolactin : the macroprolactin problem", Best Pract Res Clin Endocrinol Metab, 27, pp.725~742 (2013)
64. Hattori N, "Immunoglobulin G subclasses and prolactin(PRL)isoforms in macroprolactinemia due to anti-PRL autoantibodies", J Clin Endocrinol Metab, 90, pp.3036~3044 (2005)
65. Richa V, "Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice", J Reprod Infertil, 11, pp.161~167 (2010)
66. Fahie-Wilson M, "Polyethylene glycol precipitation : proceed with care", Ann Clin Biochem, 45, pp.233~235 (2008)
67. Barth JH, "Observational studies on macroprolactin in a routine clinical laboratory", Clin Chem Lab Med, 56, pp.1259~1262 (2018)
68. Webster R, "Immunoglobulin interference in serum follicle-stimulating hormone assays : autoimmune and heterophilic antibody interference", Ann Clin Biochem, 47, pp.386~389 (2010)
69. Ohba K, "Abnormal thyroid hormone response to TRH in a case of macro-TSH and the cut-offvalue for screening cases of inappropriate TSH elevation", Endocr J, 67, pp.125~130 (2020)
70. Loh TP, "Macro-thyrotropin : a case report and review of literature", J Clin Endocrinol Metab, 97, pp.1823~1828 (2012)
71. Rix M, "Elevated thyroid-stimulating hormone level in a euthyroid neonate caused by macro thyrotropin-IgG complex", Acta Paediatr, 100, pp.e135~e137 (2011)
72. Halsall DJ, "Macro thyrotropin-IgG complex causes factitious increases in thyroid-stimulating hormone screening tests in a neonate and mother", Clin Chem, 52, pp.1968~1969 (2006)
73. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26, pp.1~133 (2016)
74. Spencer C, "How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies", Curr Opin Endocrinol Diabetes Obes, 21, pp.394~404 (2014)
75. Giovanella L, "Thyroglobulin measurement by highly sensitive assays : focus on laboratory challenges", Clin Chem Lab Med, 53, pp.1301~1314 (2015)
76. Lupsa BC, "Autoimmune forms of hypoglycemia", Medicine(Baltimore), 88, pp.141~153 (2009)
77. Ismail AA, "The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis", Clin Chem Lab Med, 54, pp.1715~1724 (2016)
78. Lamy PJ, "High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report", Ann Biol Clin(Paris), 74, pp.490~494 (2016)
79. Piketty ML, "FGF23 measurement in burosumab-treated patients : an emerging treatment may induce a new analytical interference", Clin Chem Lab Med, 58, pp.e267~e269 (2020)
80. Mi-Na Lee, "Thyroxine (T4) Autoantibody Interference of Free T4 Concentration Measurement in a Patient With Hashimoto’s Thyroiditis", Annals of Laboratory Medicine, 37(2), pp.169~171 (2017), 대한진단검사의학회
81. Zouwail SA, "Influence of thyroid hormone autoantibodies on 7 thyroid hormone assays", Clin Chem, 54, pp.927~928 (2008)
82. Massart C, "Anti-thyroxine and anti-triiodothyronine antibody interferences in one-step free triiodothyronine and free thyroxine immunoassays", Clin Chim Acta, 401, pp.175~176 (2009)
83. Beato-Víbora PI, "Avoiding misdiagnosis due to antibody interference with serum free thyroxin", Int J Endocrinol Metab, 15, pp.e37792~ (2016)
84. Srichomkwun P, "Diagnostic dilemma in discordant thyroid function tests due to thyroid hormone autoantibodies", AACE Clin Case Rep, 3, pp.e22~e25 (2017)
85. van der Watt G, "Euthyroid patient with elevated serum free thyroxine", Clin Chem, 54, pp.1239~1241 (2008)
86. Colucci R, "Correlation of serum thyroid hormones autoantibodies with self-reported exposure to thyroid disruptors in a group of nonsegmental vitiligo patients", Arch Environ Contam Toxicol, 69, pp.181~190 (2015)
87. Papo T, "Antithyroid hormone antibodies induced by interferon-alpha", J Clin Endocrinol Metab, 75, pp.1484~1486 (1992)
88. Shimon I, "Transient elevation of triiodothyronine caused by triiodothyronine autoantibody associated with acute Epstein-Barr-virus infection", Thyroid, 13, pp.211~215 (2003)
89. Henry JG, "Interference by biotin therapy on measurement of TSH and FT4 by enzyme immunoassay on Boehringer Mannheim ES700 analyser", Ann Clin Biochem, 33, pp.162~163 (1996)
90. Trambas C, "Accurate results in the clinical laboratory", pp.83~97 (2019), Elsevier
91. Barbesino G, "Misdiagnosis of Graves’ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses", Thyroid, 26, pp.860~863 (2016)
92. Elston MS, "Factitious Graves’ disease due to biotin immunoassay interference-A case and review of the literature", J Clin Endocrinol Metab, 101, pp.3251~3255 (2016)
93. "UPDATE: the FDA warns that biotin may interfere with lab tests: FDA safety communication" (2019)[URL]
94. Piketty ML, "False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays : the problem of biotin intake and related interferences", Clin Chem Lab Med, 55, pp.780~788 (2017)
95. Carter GD, "Biotin supplementation causes erroneous elevations of results in some commercial serum 25-hydroxyvitamin D(25OHD)assays", J Steroid Biochem Mol Biol, 200, pp.105639~ (2020)
96. Plasse RA, "Biotin supplement interference with immunoassays for parathyroid hormone and 25-hydroxyvitamin D in a patient with metabolic bone disease on maintenance hemodialysis", Clin Kidney J, 13, pp.710~712 (2020)
97. Stieglitz HM, "Suspected testosterone-producing tumor in a patient taking biotin supplements", J Endocr Soc, 2, pp.563~569 (2018)
98. Bizzarri C, "Unusual presentation of a Denys–Drash syndrome girl with undisclosed assumption of biotin", J Clin Res Pediatr Endocrinol (2020)[DOI]
99. Meany DL, "A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations", Clin Chem, 55, pp.1737~1739 (2009)
100. Koehler VF, "Fake news? Biotin interference in thyroid immunoassays", Clin Chim Acta, 484, pp.320~322 (2018)
101. Ranaivosoa MK, "Chronic kidney failure and biotin: A combination inducing unusual results in thyroid and parathyroid investigations, report of 2 cases", Nephrol Ther, 13, pp.553~558 (2017)
102. Feldt MM, "Delayed diagnosis of congenital hypothyroidism in a child with trisomy 21 and biotinidase deficiency and successful use of levothyroxine sodium oral solution", Case Rep Endocrinol, 2020, pp.8883969~ (2020)
103. John JJ, "Assessment of biotin supplementation among patients in an outpatient dermatology clinic", J Am Acad Dermatol, 81, pp.620~621 (2019)
104. Lipner SR, "Update on biotin therapy in dermatology : time for a change", J Drugs Dermatol, 19, pp.1264~1265 (2020)
105. Soleymani T, "The infatuation with biotin supplementation: is there truth behind its rising popularity? A Comparative analysis of clinical efficacy versus social popularity", J Drugs Dermatol, 16, pp.496~500 (2017)
106. "PRAC recommendations on signals" (2019)[URL]
107. Katzman BM, "Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department", Clin Biochem, 60, pp.11~16 (2018)
108. Trambas CM, "Further assessment of the prevalence of biotin supplementation and its impact on risk", Clin Biochem, 65, pp.64~65 (2019)
109. Ijpelaar A, "Prevalence of detectable biotin in the Netherlands in relation to risk on immunoassay interference", Clin Biochem, 83, pp.78~80 (2020)
110. Sanders A, "Biotin immunoassay interference : a UK-based prevalence study", Ann Clin Biochem, 58, pp.66~69 (2021)
111. Goldschmidt CH, "The rise and fall of high-dose biotin to treat progressive multiple sclerosis", Neurotherapeutics, 17, pp.968~970 (2020)
112. Motte J, "High-dose biotin in multiple sclerosis : the end of the road", Lancet Neurol, 19, pp.965~966 (2020)
113. Cree BAC, "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Neurol, 19, pp.988~997 (2020)
114. Wolf B, "High doses of biotin can interfere with immunoassays that use biotin-strept(avidin)technologies : implications for individuals with biotin-responsive inherited metabolic disorders", Mol Genet Metab, 127, pp.321~324 (2019)
115. Evans N, "Immunoassay interference secondary to therapeutic high-dose biotin : A paediatric case report", J Paediatr Child Health, 54, pp.572~575 (2018)
116. Bülow Pedersen I, "Biochemical hyperthyroidism in a newborn baby caused by assay interaction from biotin intake", Eur Thyroid J, 5, pp.212~215 (2016)
117. Lefèvre CR, "Immunoassay disruption by high-dose biotin therapy : fair warning for neonatal care physicians", Pediatr Neurol, 112, pp.8~9 (2020)
118. Avery G, "Biotin interference in immunoassay : a review for the laboratory scientist", Ann Clin Biochem, 56, pp.424~430 (2019)
119. Kummer S, "Biotin treatment mimicking Graves’ disease", N Engl J Med, 375, pp.704~706 (2016)
120. Piketty ML, "High-dose biotin therapy leading to false biochemical endocrine profiles : validation of a simple method to overcome biotin interference", Clin Chem Lab Med, 55, pp.817~825 (2017)
121. Biscolla RPM, "A single 10 mg oral dose of biotin interferes with thyroid function tests", Thyroid, 27, pp.1099~1100 (2017)
122. Zhang Y, "Assessment of biotin interference in thyroid function tests", Medicine(Baltimore), 99, pp.e19232~ (2020)
123. Grimsey P, "Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference", Int J Pharmacokinet, 2, pp.247~256 (2017)
124. Peyro Saint Paul L, "Pharmacokinetics and pharmacodynamics of MD1003(high-dose biotin)in the treatment of progressive multiple sclerosis", Expert Opin Drug Metab Toxicol, 12, pp.327~344 (2016)
125. Bowen R, "Best practices in mitigating the risk of biotin interference with laboratory testing", Clin Biochem, 74, pp.1~11 (2019)
126. Gifford JL, "Strategies for mitigating risk posed by biotin interference on clinical immunoassays", Clin Biochem, 65, pp.61~63 (2019)
127. Mzougui S, "Biotin interference : evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing", Clin Chem Lab Med, 58, pp.2037~2045 (2020)
128. Lam L, "A simple method to detect biotin interference on immunoassays", Clin Chem Lab Med, 55, pp.e104~e106 (2017)
129. Trambas C, "Depletion of biotin using streptavidin-coated microparticles : a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays", Ann Clin Biochem, 55, pp.216~226 (2018)
130. Moerman A, "Sense and nonsense concerning biotin interference in laboratory tests", Acta Clin Belg, pp.1~7 (2020)
131. Rulander NJ, "Interference from anti-streptavidin antibody", Arch Pathol Lab Med, 137, pp.1141~1146 (2013)
132. Verougstraete N, "Interference of anti-streptavidin antibodies in immunoassays : A very rare phenomenon or a more common finding?", Clin Chem Lab Med, 58, pp.1673~1680 (2020)
133. Dahll LK, "Endogenous anti-streptavidin antibodies causing erroneous laboratory results more common than anticipated", Scand J Clin Lab Invest, 81, pp.92~103 (2021)
134. Berth M, "Anti-streptavidin IgG antibody interference in anti-cyclic citrullinated peptide(CCP)IgG antibody assays is a rare but important cause of false-positive anti-CCP results", Clin Chem Lab Med, 56, pp.1263~1268 (2018)
135. Raverot V, "Letter to the editor: A case of laboratory-generated “thyroid dysfunction”", Ann Endocrinol(Paris), 80, pp.140~141 (2019)
136. Lam L, "Apparent hyperthyroidism caused by biotin-like interference from IgM anti-streptavidin antibodies", Thyroid, 28, pp.1063~1067 (2018)
137. Peltier L, "Anti-streptavidin interferences in Roche thyroid immunoassays : a case report", Clin Chem Lab Med, 54, pp.e11~e14 (2016)
138. Bayart JL, "Erroneous thyroid and steroid hormones profile due to anti-streptavidin antibodies", Clin Chem Lab Med, 57, pp.e255~e258 (2019)
139. Heijboer AC, "Two cases of antiruthenium antibody interference in Modular free thyroxine assay", Ann Clin Biochem, 46, pp.263~264 (2009)
140. Buijs MM, "Interference by antiruthenium antibodies in the Roche thyroid-stimulating hormone assay", Ann Clin Biochem, 48, pp.276~281 (2011)
141. Ando T, "Non-specific activities against ruthenium crosslinker as a new cause of assay interference in an electrochemilluminescent immunoassay", Intern Med, 46, pp.1225~1229 (2007)
142. Ohba K, "Falsely elevated thyroid hormone levels caused by anti-ruthenium interference in the Elecsys assay resembling the syndrome of inappropriate secretion of thyrotropin", Endocr J, 59, pp.663~667 (2012)
143. Zaninotto M, "Interference in thyroid hormones with Roche immunoassays : an unfinished story", Clin Chem Lab Med, 52, pp.e269~e270 (2014)
144. Lim YY, "A diagnostic curiosity of isolated androstenedione elevation due to autoantibodies against horseradish peroxidase label of the immunoassay", Clin Chim Acta, 476, pp.103~106 (2018)
145. Maharjan AS, "Detection and characterization of estradiol(E2)and unconjugated estriol(uE3)immunoassay interference due to anti-bovine alkaline phosphatase(ALP)antibodies", Pract Lab Med, 17, pp.e00131~ (2019)
146. Sofronescu AG, "Spurious testosterone laboratory results in a patient taking synthetic alkaline phosphatase(asfotase alfa)", Clin Biochem, 58, pp.118~121 (2018)
147. "Class 2 device recall ST AIAPACK ACTH (ACTH)" (2021)[URL]
148. Altawallbeh G, "Letter to the Editor: assay-specific spurious ACTH results lead to misdiagnosis, unnecessary testing, and surgical misadventure–A case series", J Endocr Soc, 4, pp.bvz011~ (2019)
149. Luzzi VI, "Negative thyrotropin assay interference associated with an IgGkappa paraprotein", Clin Chem, 49, pp.709~710 (2003)
150. Imperiali M, "Interference in thyroid-stimulating hormone determination", Eur J Clin Invest, 40, pp.756~758 (2010)
151. Covinsky M, "An IgM lambda antibody to Escherichia coli produces false-positive results in multiple immunometric assays", Clin Chem, 46, pp.1157~1161 (2000)
152. Whittle E, "Pre-analytical mysteries: A case of severe hypervitaminosis D and mild hypercalcaemia", Biochem Med(Zagreb), 31, pp.011001~ (2021)
153. Ismail AA, "Interference from endogenous antibodies in automated immunoassays : what laboratorians need to know", J Clin Pathol, 62, pp.673~678 (2009)
154. Hager HB, "Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies", Clin Chem Lab Med, 59, pp.663~669 (2021)
155. Ong MW, "Artefactual 25-OH vitamin D concentration in multiple myeloma", Ann Clin Biochem, 54, pp.716~720 (2017)
156. Visser WE, "Interpretation of thyroid function tests during pregnancy", Best Pract Res Clin Endocrinol Metab, 34, pp.101431~ (2020)
157. Khoo S, "Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods", Eur J Endocrinol, 182, pp.533~538 (2020)
158. Cartwright D, "Familial dysalbuminemic hyperthyroxinemia : A persistent diagnostic challenge", Clin Chem, 55, pp.1044~1046 (2009)
159. Ross HA, "Spuriously high free thyroxine values in familial dysalbuminemic hyperthyroxinemia", Clin Chem, 57, pp.524~525 (2011)
160. Kragh-Hansen U, "Clinical, genetic, and protein structural aspects of familial dysalbuminemic hyperthyroxinemia and hypertriiodothyroninemia", Front Endocrinol(Lausanne), 8, pp.297~ (2017)
161. DeCosimo DR, "Prevalence of familial dysalbuminemic hyperthyroxinemia in Hispanics", Ann Intern Med, 107, pp.780~781 (1987)
162. Pappa T, "Inherited defects of thyroxine-binding proteins", Best Pract Res Clin Endocrinol Metab, 29, pp.735~747 (2015)
163. Campi I, "The differential diagnosis of discrepant thyroid function tests: insistent pitfalls and updated flow-chart based on a long-standing experience", Front Endocrinol(Lausanne), 11, pp.432~ (2020)
164. Dieu X, "Familial dysalbuminemic hyperthyroxinemia : an underdiagnosed entity", J Clin Med, 9, pp.2105~ (2020)
165. Rosner W, "Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement", J Clin Endocrinol Metab, 92, pp.405~413 (2007)
166. Keevil BG, "Assessment of free testosterone concentration", J Steroid Biochem Mol Biol, 190, pp.207~211 (2019)
167. Faye SA, "Investigation and resolution of the effect of an interfering factor in the Beckman Coulter anti-Müllerian hormone(AMH)Gen II ELISA assay", Hum Reprod, 29, pp.331~ (2014)
168. Turner KA, "Assessment of complement interference in anti-Müllerian hormone immunoassays", Clin Chem Lab Med, 58, pp.e8~e10 (2020)
169. Monaghan PJ, "Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service study", Clin Endocrinol(Oxf), 85, pp.569~574 (2016)
170. Lauro C, "What to do in the event of a suspicion of analytical interference during an immunoassay?", Ann Biol Clin(Paris), 78, pp.70~73 (2020)
171. Gurnell M, "What should be done when thyroid function tests do not make sense?", Clin Endocrinol(Oxf), 74, pp.673~678 (2011)
172. Cavalier E, "False positive PTH results : an easy strategy to test and detect analytical interferences in routine practice", Clin Chim Acta, 387, pp.150~152 (2008)
173. Ellis MJ, "Techniques for identifying heterophile antibody interference are assay specific : study of seven analytes on two automated immunoassay analyzers", Clin Chem, 51, pp.639~641 (2005)
174. Choy KW, "Immunoassay interference complicating management of Cushing’s disease : the onus is on the clinician and the laboratory", Ann Clin Biochem, 54, pp.183~184 (2017)
175. Faix JD, "Principles and pitfalls of free hormone measurements", Best Pract Res Clin Endocrinol Metab, 27, pp.631~645 (2013)
176. Ismail AA, "On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test", Clin Chem Lab Med, 45, pp.851~854 (2007)
177. Cole LA, "Easy fix for clinical laboratories for the false-positive defect with the Abbott AxSym total β-hCG test", Clin Biochem, 37, pp.344~349 (2004)
178. Santhana Krishnan SG, "Falsely raised TSH levels due to human anti-mouse antibody interfering with thyrotropin assay", Postgrad Med J, 82, pp.e27~ (2006)
179. "Interlaboratory survey of methods for measuring human anti-mouse antibodies. HAMA Survey Group", Clin Chem, 38, pp.172~173 (1992)
180. Favresse J, "Anti-streptavidin antibodies mimicking heterophilic antibodies in thyroid function tests", Clin Chem Lab Med, 56, pp.e160~e163 (2018)
181. Giovanella L, "Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia", Clin Chem Lab Med, 56, pp.e191~e193 (2018)
182. Wong T, "Identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioimmunoassays", Clin Chem, 38, pp.1830~1837 (1992)
183. Makela SK, "Nonspecificity of a direct 17 alpha-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates", Clin Chem, 34, pp.2070~2075 (1988)
184. Hawley JM, "Serum cortisol : an up-to-date assessment of routine assay performance", Clin Chem, 62, pp.1220~1229 (2016)
185. Vogeser M, "Multicenter performance evaluation of a second generation cortisol assay", Clin Chem Lab Med, 55, pp.826~835 (2017)
186. Thomas CM, "Inaccurate measurement of 17 beta-estradiol in serum of female volunteers after oral administration of milligram amounts of micronized 17 beta-estradiol", Clin Chem, 39, pp.2341~2342 (1993)
187. Nahoul K, "Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone", J Steroid Biochem, 26, pp.241~249 (1987)
188. Taieb J, "Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children", Clin Chem, 49, pp.1381~1395 (2003)
189. Warner MH, "Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone", Ann Clin Biochem, 43, pp.196~199 (2006)
190. Piketty ML, "Clinical comparison of three labeled-antibody immunoassays of free triiodothyronine", Clin Chem, 42, pp.933~941 (1996)
191. Krasowski MD, "Cross-reactivity of steroid hormone immunoassays : clinical significance and two-dimensional molecular similarity prediction", BMC Clin Pathol, 14, pp.33~ (2014)
192. Dias ML, "Detecting and solving the interference of pregnancy serum, in a GH immunometric assay", Growth Horm IGF Res, 23, pp.13~18 (2013)
193. Schiettecatte J, "Performance evaluation of an automated electrochemiluminescent calcitonin(CT)immunoassay in diagnosis of medullary thyroid carcinoma", Clin Biochem, 49, pp.929~931 (2016)
194. Hillebrand JJ, "Falsely decreased thyroglobulin levels in a patient with differentiated thyroid carcinoma", Clin Chim Acta, 509, pp.217~219 (2020)
195. Cormano J, "Gestational trophoblastic disease diagnosis delayed by the hook effect", Obstet Gynecol, 126, pp.811~814 (2015)
196. Pillay Tahir S., "Application of Single-Domain Antibodies (“Nanobodies”) to Laboratory Diagnosis", Annals of Laboratory Medicine, 41(6), pp.549~558 (2021), 대한진단검사의학회[DOI]